European cooperation in the field of scientific and technical research

New strategies in drug development and clinical evaluation: The population approach

Conference held in Manchester, UK
21 to 23 September 1991

Edited by:
Malcolm Rowland and Leon Aarons
(for the Management Committee of the COST B1 project)

Commission of the European Communities
rue de la Loi 200
B-1049 Brussels
Contents

Preface vii
Foreword ix

1. Overview

Drug development today
   F. Parenti 3

Population approach in drug development: rationale and basic concepts
   L.B. Sheiner 13

Population models and methods, with emphasis on pharmacokinetics
   J.-L. Steimer 31

The population approach; applications to date. An overview
   B. Whiting 41

General discussion 59

2. Experiences with population methods

Experiences with population methods: the NONMEM system
   T. Ludden 65

Experiences with NPML: application to dosage individualisation of cyclosporine, gentamicin and zidovudine
   F. Mentré 75

A Bayesian approach to the prediction of the plasma concentration range of carbamazepine in epileptic patients
   A. Racine-Poon 91

Statistical issues in population methods
   R. O’Neill 99

Applications of population approach to clinical pharmacokinetics and validation of the results
   S. Vozeh 107

3. Population approaches in pharmacokinetics

Current experience of population pharmacokinetics within the pharmaceutical industry - an introduction
   R. Jochemsen 127
An evaluation of population pharmacokinetics during drug development: experiences with graphical exploratory analysis for isradipine and tropisetron  
   J.-L. Steimer  

Population pharmacokinetics during drug development: experience within Parke-Davis  
   S. Olson  

Population approach in pharmacokinetics and pharmacodynamics - views within regulatory agencies: Europe  
   U.A. Gundert-Remy  

Population approach in pharmacokinetics and pharmacodynamics: FDA view  
   C. Peck  

Practical issues in possible implementation of population pharmacokinetics in drug development - discussion  
   L. Aarons  

4. Further applications and issues of population methods  

The population approach: applications to experimental data  
   N. Sambol  

Parametric models for the time course of drug action: the population approach  
   N. Holford  

Pharmacodynamic measures based on CD4 lymphocyte counts for assessing the effect of anti-HIV therapy  
   L. Sanathanan  

Population approach in post-marketing dose adjustment  
   Y. Tanigawara  

Identification of target population and responders  
   J.P. Boissel  

Closing address  
   M. Rowland  

List of participants  

Index